

[Nifurtimox](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.5. Antitrypanosomal medicines](#) [6.5.5.1. African trypanosomiasis](#) [6.5.5.1.2. Medicines for the treatment of 2nd stage African trypanosomiasis](#)

ATC codes: [P01CC01](#)

EMLc

Indication

Gambiense trypanosomiasis ICD11 code: [1F51.0](#)

INN

Nifurtimox

Medicine type

Chemical agent

List type

Core

Additional notes

Only to be used in combination with eflornithine, for the treatment of Trypanosoma brucei gambiense infection.

Formulations

Oral > Solid > tablet: 30 mg (scored) ; 120 mg (scored)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2013 ([TRS 985](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Nifurtimox](#)

DrugBank

[Nifurtimox](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of nifurtimox 250 mg tablets from the EML and EMLc, and the addition of nifurtimox 30 mg tablets to the EMLc (Section 6.5.5.1).